Positive News SentimentPositive NewsNASDAQ:LYEL Lyell Immunopharma (LYEL) Stock Price, News & Analysis $0.61 -0.03 (-4.41%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Lyell Immunopharma Stock (NASDAQ:LYEL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lyell Immunopharma alerts:Sign Up Key Stats Today's Range$0.60▼$0.6450-Day Range$0.59▼$1.4852-Week Range$0.58▼$3.26Volume2.81 million shsAverage Volume1.06 million shsMarket Capitalization$179.01 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingReduce Company OverviewLyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Read More… Lyell Immunopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreLYEL MarketRank™: Lyell Immunopharma scored higher than 47% of companies evaluated by MarketBeat, and ranked 622nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingReduce Consensus RatingLyell Immunopharma has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageLyell Immunopharma has only been the subject of 2 research reports in the past 90 days.Read more about Lyell Immunopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lyell Immunopharma are expected to decrease in the coming year, from ($0.80) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyell Immunopharma is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyell Immunopharma is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyell Immunopharma has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.22% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Lyell Immunopharma has recently decreased by 1.56%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLyell Immunopharma does not currently pay a dividend.Dividend GrowthLyell Immunopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.22% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Lyell Immunopharma has recently decreased by 1.56%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News SentimentN/A News SentimentLyell Immunopharma has a news sentiment score of 1.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Lyell Immunopharma this week, compared to 1 article on an average week.Search Interest5 people have searched for LYEL on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lyell Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders25.10% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyell Immunopharma's insider trading history. Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LYEL Stock News HeadlinesLyell Immunopharma Inc Ordinary SharesDecember 12, 2024 | morningstar.comLyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual MeetingDecember 9, 2024 | globenewswire.comThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… December 22, 2024 | Crypto 101 Media (Ad)Mitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market ChallengesNovember 13, 2024 | markets.businessinsider.comThe Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 ExpertsNovember 12, 2024 | benzinga.comLyell Immunopharma reports Q3 net loss $44.6M vs. $50.9M last yearNovember 9, 2024 | markets.businessinsider.comLyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024November 8, 2024 | markets.businessinsider.comLyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual MeetingNovember 5, 2024 | globenewswire.comSee More Headlines LYEL Stock Analysis - Frequently Asked Questions How have LYEL shares performed this year? Lyell Immunopharma's stock was trading at $1.94 at the beginning of the year. Since then, LYEL stock has decreased by 68.4% and is now trading at $0.6127. View the best growth stocks for 2024 here. How were Lyell Immunopharma's earnings last quarter? Lyell Immunopharma, Inc. (NASDAQ:LYEL) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03. The business earned $0.03 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative trailing twelve-month return on equity of 34.64%. When did Lyell Immunopharma IPO? Lyell Immunopharma (LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO. Who are Lyell Immunopharma's major shareholders? Lyell Immunopharma's top institutional investors include WuXi AppTec Co. Ltd. (2.89%), State Street Corp (1.39%), Charles Schwab Investment Management Inc. (0.45%) and FMR LLC (0.37%). View institutional ownership trends. How do I buy shares of Lyell Immunopharma? Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lyell Immunopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyell Immunopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW). Company Calendar Last Earnings11/07/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LYEL CUSIPN/A CIK1806952 Webwww.lyell.com Phone650-695-0677FaxN/AEmployees270Year FoundedN/APrice Target and Rating Average Stock Price Target$1.00 High Stock Price Target$1.00 Low Stock Price Target$1.00 Potential Upside/Downside+63.2%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-234,630,000.00 Net Margins-323,792.09% Pretax Margin-323,792.09% Return on Equity-34.64% Return on Assets-30.02% Debt Debt-to-Equity RatioN/A Current Ratio13.43 Quick Ratio13.43 Sales & Book Value Annual Sales$63,000.00 Price / Sales2,841.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.60 per share Price / Book0.24Miscellaneous Outstanding Shares292,162,000Free Float218,829,000Market Cap$179.01 million OptionableOptionable Beta-0.45 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:LYEL) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.